[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-decompensated-heart-failure-adhf\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-decompensated-heart-failure-adhf":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,70,104,127,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100595892","phase-3-effects-of-continued-administration-of-empagliflozin-in-patients-with-heart-failure-on-active-sglt2-inhibitor-treatment-admitted-for-acute-decompensated-heart-failure-100595892",false,"NCT07038356","Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure","EMPA-CON","Inclusion Criteria:\n\n* Patients (age ≥ 18 years) with acute decompensated heart failure (HF) according to clinical assessment on active therapy with a SGLT2 inhibitor\n* Brain Natriuretic Peptide (BNP) \\>100 pg\u002Fml or N-terminal pro-BNP (NTproBNP) \\>300 pg\u002Fml\n* Written informed consent obtained\n* Women of childbearing potential: negative pregnancy test and use of a highly effective method of contraception\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Chronic Kidney Disease (CKD) with eGFR\\\u003C20 ml\u002Fmin, or end-stage renal failure with the need for chronic dialysis treatment\n* Acute kidney injury (AKI) requiring dialysis treatment\n* Known intolerance to empagliflozin\n* Acute heart failure without signs of congestion (\"dry\" patient)\n* Indication for coronary angiography or any foreseeable administration of a contrast media\n* Need for hemofiltration or any other form of extracorporeal therapy\n* Planned surgery\n* Previous participation in this trial or recent participation in another clinical trial (within the last 4 weeks before inclusion)\n* Identification of any causes of heart failure leading to decompensation that needs urgent management (like acute coronary syndrome, severe unstable arrhythmias, mechanical causes, acute pulmonary embolism)\n* Incapacity to understand and \u002F or to provide written informed consent\n* Obvious uncontrolled substance abuse\n* Pregnancy, breastfeeding","ALL","18 Years",{"count":19,"type":20},536,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this clinical trial is to test the hypothesis that the continuation of empagliflozin during decongestive therapy in the setting of acute decompensated and hospitalized heart failure patients is not inferior compared to therapy cessation during the acute heart failure hospitalization.\n\nRandomized treatment (plus standard medical care) in patients with acute decompensated heart failure is one (1) tablet daily of empagliflozin 10 mg or matching placebo during the in-hospital stay (up to a maximum of 30 days), followed by treatment with empagliflozin 10 mg daily after discharge (but no later than day 31) until day 90.\n\nThe primary outcome measure is the combined hierarchical endpoint of all-cause mortality, heart failure hospitalization and worsening renal function at 90 days after admission.\n\nSecondary outcome measures are the effects on urine output, diuretic efficiency, quality-of-life and the need for further administration of diuretics.\n\nParticipants will\n\n* Take one tablet of study medication once daily (day 1 to day 90)\n* Restrict fluid intake to 1.5 liters of fluid per day and record the daily fluid intake for the study from day 1 to day 6 in the patient diary\n* Measure the urine output (day 1 to day 6)\n* Fill in Questionnaires (EQ-5D-3L (3-level version of the EuroQol five dimensional descriptive system), KCCQ-12 (Kansas City Cardiomyopathy Questionnaire comprising 12 items)) on day 0 (Baseline), at hospital discharge, and on day 30",[26],"Acute Decompensated Heart Failure (ADHF)","RECRUITING","2026-03-30",{"date":30,"type":31},"2026-04-01","ACTUAL",{"date":33,"type":31},"2025-12-08",{"date":35,"type":20},"2026-06-30",{"name":37,"class":38},"Christian Schulze","OTHER",9,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100621930","efficacy-and-safety-of-compression-boots-in-patients-with-acute-decompensated-heart-failure-100621930","NCT07377019","Efficacy and Safety of Compression Boots in Patients With Acute Decompensated Heart Failure.","The Efficacy and Safety of Pulsatile Compression Boots in Patients With Acute Decompensated Heart Failure. A Randomized, Controlled Trial.","COMPLEX","Inclusion Criteria:\n\n* Capable of giving written informed consent\n* Inclusion within 24 hours from admission\n* Bilateral LE edema - defined as: Pitting edema scale \\> 1, bilaterally\n* Initial IV diuretic treatment\n\nEvidence of heart failure - at least one of the following:\n\n1. Heart failure with reduced ejection fraction (HFrEF):\n\n   * Signs and\u002For symptoms of HF\n   * Left ventricular ejection fraction (LVEF) ≤ 40%\n2. Heart failure with mildly reduced ejection fraction (HFmrEF):\n\n   * Signs and\u002For symptoms of HF\n   * LVEF 41 - 49%\n3. Heart failure with preserved ejection fraction (HFpEF):\n\n   * Signs and\u002For symptoms of HF\n   * LVEF ≥ 50 %\n   * Evidence of structural heart disease (Left atrial enlargement or left ventricular hypertrophy)\n   * NT-proBNP \\> 300pg\u002FmL for patients without ongoing atrial fibrillation\u002Fflutter, and NT-proBNP \\> 600 pg\u002FmL for patients with ongoing atrial fibrillation\u002Fflutter.\n\nEvidence of elevated pulmonary artery pressure - at least one of the following:\n\n* Systolic pulmonary artery pressure (sPAP) \\> 35 mmHg\n* Tricuspid regurgitation gradient (TRG) \\> 30 mmHg\n* Severe tricuspid regurgitation and VCI \\> 20 mm.\n\nAdditional echocardiographic criteria:\n\n\\- Left atrial end-systolic volume index \\> 34 mL\u002Fm2\n\nExclusion Criteria:\n\n* Pregnancy\n* Life expectancy less than 1 year for any reason\n* Expected hospital stay less than 1 day\n* New York Heart Association classification (NYHA) class IV\n* LVEF \\\u003C 20%\n* Diastolic left ventricular diameter \\> 70 mm\n* Known history or symptoms of peripheral arterial disease (Intermittent claudication or brachial-ankle index with value \\\u003C 0,9)\n* Significant leg wounds or infections\n* Deep venous thrombosis (DVT)\n* Need for treatment with inotropes or vasopressors\n* Permanent dialysis\n* Manifest acute kidney injury with oliguria\n* Current high-pressure pulmonary edema",{"count":49,"type":20},100,[51],"NA","The aim of this clinical trial is to investigate whether pulsatile compression therapy can support heart and kidney function in patients admitted with acute heart failure and fluid accumulation in the legs.\n\nPulsatile compression boots, which provide pulsatile compression therapy, work by adding a predefined pressure to the legs in a rhythm that enhances mobilization of peripheral edema and improves venous and lymphatic drainage from the lower extremities. This increased venous return (preload) may allow the heart to fill more effectively and pump more strongly, thereby improving circulation. Better circulation can enhance kidney blood flow, help diuretics work more efficiently, and reduce the risk of complications due to worsening heart failure, affecting both the heart and kidneys.\n\nThe investigators want to explore whether adding this therapy to standard diuretic treatment is safe, feasible, and offers benefits compared with standard diuretic treatment alone.\n\nParticipants will receive three daily sessions of pulsatile compression therapy alongside usual clinical care.",[26],[55,56,57,58],"Acute Decompensated Heart Failure","Heart failure","Compression therapy","Cardiorenal syndrome","NOT_YET_RECRUITING","2026-01-21",{"date":62,"type":31},"2026-01-29",{"date":64,"type":20},"2026-01",{"date":66,"type":20},"2028-04",{"name":68,"class":38},"Odense University Hospital",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":5},"100613141","phase-2-levosimendan-in-acute-decompensated-heart-failure-100613141","NCT07262723","Levosimendan in Acute Decompensated Heart Failure","Efficacy and Safety of Levosimendan in Patients With Acute Decompensated Heart Failure: A Real-World Evidence","Inclusion Criteria:\n\n* Adult patients (age \\>18 years)\n* Both male and female sex\n* Having left ventricular dysfunction, evidenced by a left ventricular ejection fraction \\\u003C40% within the prior 12 months\n* Hospitalized for the treatment of ADHF\n* Remained dyspneic at rest despite treatment with intravenous diuretics (NYHA class IV)\n* Patients might have received intravenous vasodilators and\u002For positive inotropic drugs (except amrinone and milrinone), but the infusion rates of these drugs must have remained constant for at least 2 h before entry into the study.\n\nExclusion Criteria:\n\n* History of invasive cardiac procedure\n\n  * Cardiac surgery during lifetime within 3 months prior to screening\n  * Cardiac revascularization within 3 months prior to screening\n  * Left ventricular assist device (LVAD) implantation within 3 months prior to screening\n  * A cardioversion within 4 h prior to screening, or\n  * Cardiac re-synchronization procedure within 30 days prior to screening)\n* Rhythm disorders (e.g. earlier Torsades de Pointes, increased heart rate)\n* Severe ventricular outflow obstruction\n* Angina within 6 h prior to screening\n* Hypotension (a systolic blood pressure \\\u003C90 mmHg) \\[Can be included after resuscitation, when SBP will be \\>90 mmHg by noradrenaline infusion\\]\n* Uncorrected hypokalemia\n* CNS disease (e.g. stroke, TIA)\n* Respiratory (e.g. COPD exacerbation requiring systematic steroids or intubation)\n* Renal insufficiency (e.g. increased serum creatinine clearance rate \\\u003C15 mL\u002Fmin)\n* Hepatic impairment (e.g. significant increase in liver enzymes, \\>5x the upper limit of normal)\n* Decompensation from active infection eg, sepsis\n* Acute bleeding\n* Patient required blood transfusion or Severe anemia (hemoglobin \\\u003C8 g\u002Fl)\n* Serum potassium concentration \\\u003C3.5 or \\>5.4 mmol\u002Fl\n* Use of amrinone and milrinone prior to screening\n* A history of hypersensitivity to levosimendan or any of the excipients\n* Intubated or otherwise unable to communicate\n* Pregnancy\n* Post partum cardiomyopathy\n* Previous participation in a clinical trial with any experimental treatment within the last 30 days",{"count":78,"type":20},332,[80,23],"PHASE2","Acute decompensated heart failure (ADHF) is one of the major causes of hospitalization and mortality worldwide. Despite advances in medical treatments, managing ADHF remains complex, especially in high-risk populations. Levosimendan, a calcium sensitizer that improves myocardial contractility and reduces complications associated with acute decompensated heart failure, has shown potential in improving outcomes in these patients. The present study aims to evaluate the efficacy and safety of levosimendan in patients with ADHF in a real-world clinical setting.\n\nThis pragmatic, multicenter, randomized, controlled trial will include adult patients diagnosed with ADHF in two groups: one receiving levosimendan infusion, and the other receiving standard care for heart failure management, according to the most up-to-date clinical protocols. The study is designed to assess both the efficacy and safety of levosimendan, comparing it with the current standard of care.\n\nThe primary endpoint of the study will be a clinical composite outcome measured from the NYHA functional classification of heart failure and patient global assessment. Secondary endpoints will include change in serum pro-BNP levels, clinical outcome of heart failure, changes in dyspnea status, all-cause and cardiac mortality. Safety endpoints, including adverse events, will also be systematically recorded and analyzed. Adverse events will be closely monitored, categorized as either mild, moderate, or severe, and their potential association with the treatment will be assessed.\n\nData collection will occur at baseline and during subsequent follow-up visits at 6 hours, 24 hours, 5 days (or day of discharge), and 90 days post-treatment. Key efficacy measures will be obtained through clinical evaluations and laboratory tests, including blood pressure, electrocardiogram (ECG) findings, and NT-proBNP serum levels. The statistical analysis will follow an intention-to-treat (ITT) and Per protocol (PP) approach to account for all enrolled patients, ensuring robust and generalizable findings. This study will be conducted in accordance with Good Clinical Practice (GCP) guidelines and ethical standards outlined in the Declaration of Helsinki, prioritizing participant safety and scientific rigor throughout the study.\n\n12 The results of this trial will provide critical insights into the potential benefits of levosimendan for treating ADHF, and could potentially inform clinical decision-making, offering a more effective therapeutic option in managing this life-threatening condition.",[26],[84,85,86,87,88,89,90,91,92,93,94],"Acute decompensated heart failure (ADHF)","Levosimendan","Real-world evidence","Efficacy","Safety","NT-proBNP \u002F pro-BNP levels","Randomized controlled trial (RCT)","Electrocardiogram (ECG)","Good Clinical Practice (GCP)","Declaration of Helsinki","Adverse events","2025-11-23",{"date":97,"type":31},"2025-12-04",{"date":99,"type":20},"2025-12-01",{"date":101,"type":20},"2026-12-30",{"name":103,"class":38},"Chittagong Medical College",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":69},"100598832","phase-4-the-effect-of-dapagliflozin-on-patients-with-cardiomyopathy-100598832","NCT07076615","The Effect of Dapagliflozin on Patients With Cardiomyopathy","Dapagliflozin","Inclusion Criteria:\n\n* 18 years or older\n* Acute heart failure as defined by the 2022 American College of Cardiology\u002FAmerican Heart Association (Heidenreich et al., 2022) or 2021 European Society of Cardiology (McDonagh et al., 2021) guidelines, based on typical symptoms and signs of heart failure requiring hospitalization or emergency department visit\n* Elevated natriuretic peptide levels\n* Includes heart failure with reduced, mildly reduced, or preserved ejection fraction\n* Planned use of intravenous diuretic therapy\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Urinary tract or genital infection\n* Hypovolemia\n* Diabetic ketoacidosis\n* Serum glucose \\\u003C 80 mg\u002FdL at enrollment\n* Systolic blood pressure \\\u003C 90 mmHg at enrollment\n* History of hypersensitivity to any SGLT2 inhibitor\n* Pregnant or breastfeeding women\n* Severe primary valvular lesion requiring intervention\n* Severe hepatic impairment (Child-Pugh class C)\n* Estimated glomerular filtration rate \\\u003C 25 mL\u002Fmin\u002F1.73 m² (by MDRD equation)",{"count":49,"type":20},[113],"PHASE4","This randomized controlled trial evaluates the efficacy and tolerability of early initiation of dapagliflozin in adult patients hospitalized with acute heart failure (AHF). The study aims to assess the effect of dapagliflozin on pulmonary congestion as measured by lung ultrasound (LUS), length of hospital stay, and cardiac and renal biomarkers. A total of 100 patients will be randomized into two groups: one receiving dapagliflozin plus diuretics and the other receiving diuretics alone. Key outcomes include the reduction of extravascular lung water (assessed by B-lines in LUS), improved diuretic response, changes in NT-proBNP, sST2, CA-125, and NGAL levels, and incidence of acute kidney injury. The study will be conducted at the Cardiology and ICU departments at Kasr Al Ainy Hospital, Cairo University",[26],[117],"ADHF","2025-08-17",{"date":120,"type":31},"2025-08-22",{"date":122,"type":20},"2025-08",{"date":124,"type":20},"2026-05",{"name":126,"class":38},"May Mohamed Abdalla",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":148,"locationsCount":69},"100577241","excrs-effects-and-safety-in-vulnerable-adhf-patients-100577241","NCT06795737","ExCR's Effects and Safety in Vulnerable ADHF Patients","Effectiveness and Safety of Exercise-based Cardiac Rehabilitation (ExCR) During the Vulnerable Period in Patients With Acute Decompensated Heart Failure (ADHF): A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Hospitalized for ADHF for over 24 hours.\n2. Age 18-80 years.\n3. At least one acute heart failure symptom: dyspnea at rest or exertion, fatigue, orthopnea, or paroxysmal nocturnal dyspnea.\n4. At least two heart failure signs: confirmed pulmonary congestion or edema on exam or chest X-ray, jugular venous distension, peripheral edema, rapid weight gain (\\>2 kg in 3 days), or elevated BNP (≥100 ng\u002FL) and NT-proBNP (≥300 ng\u002FL).\n5. Change in heart failure treatment plan with initiation or increased dosage of: diuretics, vasodilators, positive inotropic agents (e.g., digoxin), or other neurohormonal modulators (ACEI\u002FARB\u002FARNI, β-blocker, MRA).\n\nExclusion Criteria:\n\n1. Indications for urgent cardiovascular surgery (e.g., heart transplantation, left ventricular assist device).\n2. Cardiogenic shock.\n3. Recent deep vein thrombosis.\n4. Severe cardiovascular diseases (e.g., severe aortic stenosis, mitral regurgitation).\n5. GFR \\\u003C30 ml\u002Fmin or need for dialysis during the study.\n6. Severe COPD (FEV1\u002FFVC \\\u003C0.7 post-bronchodilator, with severe defined as 30% ≤ FEV1 \\\u003C50% predicted, and very severe as FEV1 \\\u003C30% predicted).\n7. Severe frailty (Clinical Frailty Scale CFS ≥7).\n8. Mental, psychological, cognitive disorders, or substance dependence.","80 Years",{"count":136,"type":20},88,[51],"Exercise-based cardiac rehabilitation has become a key component of the comprehensive care system for patients with stable heart failure (HF). However, due to hemodynamic instability and functional decline in early ADHF, most HF rehab studies exclude current\u002Frecent ADHF exacerbations. Currently, ADHF management strategies lack robust evidence, and the timing, duration, and frequency of exercise interventions need further validation globally.\n\nThis study aims to address the following issues:\n\nDevelop an exercise management program for ADHF patients, verify its feasibility, and determine the safety and applicability of early exercise rehabilitation; Evaluate the improvement of participants in terms of physical function, cardiac function, and quality of life.\n\nThe research team will compare the formulated exercise rehabilitation program with conventional rehabilitation guidance to verify its feasibility and effectiveness.\n\nParticipants will:\n\nPhysicians and rehabilitation therapists will comprehensively assess the participants' conditions to determine the start time of rehabilitation training. Based on the patients' cardiac function, muscle strength, and heart failure-related clinical indicators, rehabilitation training is divided into two stages (the first stage is early in-hospital training, and the second stage is self-directed training after discharge). Exercise types mainly include respiratory training, bed activities, rehabilitation pedaling, and resistance training. Rehabilitation therapists and nurses will monitor participants' vital signs during the exercise process and choose the appropriate exercise intensity based on the participants' level of fatigue.\n\nThe exercise rehabilitation program will be evaluated and adjusted every two weeks for a total period of 12 weeks.\n\nAt the time of enrollment, discharge, two weeks after discharge, and four weeks after discharge, participants will need to complete questionnaires, including demographic and disease condition surveys, grip strength tests, Activities of Daily Living (ADL) scales, Short Physical Performance Battery (SPPB) scales, Minnesota Living with Heart Failure Questionnaire (MLHFQ) scales, and 6-minute walk tests, etc.",[26],[141],"Acute Decompensated Heart Failure (ADHF)；Vulnerable Phase；Exercise Rehabilitation；RCT","2025-01-26",{"date":144,"type":31},"2025-01-28",{"date":146,"type":20},"2025-02-17",{"date":35,"type":20},{"name":149,"class":38},"YE Jing",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":5},"100567659","noninvasive-assessment-of-pulmonary-fluid-levels-by-remote-dielectric-sensing-technology-to-improve-cardiac-insufficieney-during-ischemia-reperfusion-and-clinical-outcomes-in-myocardial-infarction-100567659","NCT06671067","Noninvasive Assessment of Pulmonary Fluid Levels by Remote Dielectric Sensing Technology to Improve Cardiac InsUfficieney During Ischemia-Reperfusion and Clinical Outcomes in MyocArdiaL Infarction","Noninvasive Assessment of Pulmonary Fluid Levels by Remote Dielectric Sensing (ReDS™) Technology to Improve Cardiac Insufficiency During Ischemia-reperfusion and Clinical Outcomes in Myocardial Infarction","NATURAL","Inclusion Criteria:\n\n1. Patients were required to be aged ≥ 18 years and to be hospitalized for a primary diagnosis of AMI,\n2. AMI patients accompanied by cardiac insufficiency following coronary revascularization, which is characterized by the symptoms and signs of fluid overload, regardless of left ventricular ejection fraction (LVEF), and have an N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration of ≥ 400 pg\u002FL or a BNP concentration of ≥ 100 pg\u002FL.\n\nExclusion Criteria:\n\n1. Patient's physical characteristics that prevented the use of the ReDS system (height of \\\u003C155 or \\>190 cm; body mass index of \\\u003C22 or \\>39 kg\u002Fm2)\n2. Patients with chronic obstructive pulmonary disease or other lung diseases that might confound ReDS values\n3. Patients with a left ventricular assist device or undergoing cardiac transplantation;\n4. Patients with congenital heart malformations or intrathoracic mass that would affect right lung anatomy;\n5. Patients with end-stage renal disease on hemodialysis;\n6. Patients whose life expectancy less than 12 months due to noncardiac comorbidities\n7. Patients who participate in another randomized studies.",{"count":159,"type":20},2000,[51],"To explore whether a ReDS-guided strategy for AMI patients with cardiac insufficiency following coronary flow reperfusion is superior to routine care for improving outcomes.",[163,26],"Acute Myocardial Infarction",[165,166,167,168],"Remote dielectric sensing system","Acute myocardial infarction","Acute heart failure","Clinical outcomes","2024-10-31",{"date":171,"type":31},"2024-11-04",{"date":173,"type":20},"2024-11-01",{"date":175,"type":20},"2027-06",{"name":177,"class":38},"Shanghai 10th People's Hospital"]